Bayer logo
US MEDICAL AFFAIRS
Contact Us icon

Publications

Publications

Home / Publications 

We invite you to explore Bayer-supported publications. This library is not intended to serve as a comprehensive repository of all publications. Publications not supported by Bayer are not included. Access to the full text of publications may depend on journal access rights.

To help narrow down your search, choose the relevant tags and click Apply. Selecting multiple tags will narrow your results.

Last updated April 2026.

IPPI: Immediate Postpartum Insertion

SD: Sleep Disturbances

PK: Pharmacokinetics

IUD: Intrauterine Device

VMS: Vasomotor Symptoms

Types of Enhancements Available

To help narrow down your search, select the relevant filters from the dropdowns and Click Apply

Hold down Ctrl key on keyboard to select multiple years

Total available publications: 46    

Filtered results: 46

Liver Safety of the Dual Neurokinin-1/-3 Receptor Antagonist Elinzanetant

Lewis JH, et al. Drug Saf. 2026. Online ahead of print

Lewis J.H., Andrade R.J., Larrey D., Horsmans Y., Anderson R.A.,,
READ
EMAIL

The burden of sleep disturbances on quality of life and mental well-being in nearly 50,000 perimenopausal and postmenopausal women with and without concurrent vasomotor symptoms from the United States and Europe

Soares CN, et al. Menopause. 2026; 33(3):261-269

Soares C. N., Briggs P., Dinkel-Keuthage C., Schoof N., Moeller ,
READ
EMAIL

Medical habit or necessity? Investigating misoprostol use for IUD insertion in Europe

Eggebrecht L, et al. Eur J Contracept Reprod Health Care. 2026. Online ahead of print

Eggebrecht L., Rizzo M., Klinghardt M., Boehnke T., Barnett C., ,
READ
EMAIL

Polished but pointless? Assessing the potential of gold and silver-alloy IUDs versus copper-only devices in a large multinational cohort (EURAS-LCS12)

Boehnke T, et al. Eur J Contracept Reprod Health Care. 2026. Online ahead of print

Boehnke T., Eggebrecht L., Rizzo M., Klinghardt M., and Heineman,
READ
EMAIL

Associations between vasomotor symptoms, sleep disturbances, and frequent mood changes individually and within symptom groups across the menopausal transition and early postmenopause: observations from the Study of Women's Health Across the Nation

Maki P, et al. Menopause. 2026. Online ahead of print

Maki P.M., Inan Eroglu E., Janssenswillen C., Frenz A.K., Heeg S,
READ
EMAIL

Impact of sleep disturbances on health-related quality of life in postmenopausal women: a systematic review

Soares C, et al. Menopause. 2026; 33(1):118-128

Soares C.N., Bajbouj M., Schoof N., Kishore A., and Caetano C. ,
READ
EMAIL

Putting Theory into Practice by Developing a Novel Digital Health Technology-Derived Endpoint in Sleep Quality

Kramer F, et al. Digit Biomark. 2025; 10(1):1-10.

Kramer F., Krauss J., Pal J., Batchelor J., Yuksel P., O Sulliva,
READ
EMAIL

Treatment patterns in women with breast cancer and endocrine therapy-related menopausal symptoms: a cohort study from the United States, United Kingdom, and Germany

Saadedine M, et al. Menopause. 2025; 32(12):1111-1119.

Saadedine M, Banks V, Dinkel-Keuthage C, Janssenswillen C, Laval,
READ
EMAIL

The burden of sleep disturbances and vasomotor symptoms on work productivity, activity impairment and healthcare resource use in perimenopausal and postmenopausal women

Briggs P, et al. Maturitas. 2025. 203:108758.

Briggs P., Dinkel-Keuthage C., Nguyen J., Schoof N., Moeller C.,,
READ
EMAIL

Use of oral medications prior to IUD insertion - Trends and associations of patient characteristics in a large observational study in Europe (EURAS-LCS12)

Klinghardt M, et al. Eur J Obstet Gynecol Reprod Biol. 2025. Online ahead of print

Klinghardt M., Rizzo M., Boehnke T., Barnett C., Heinemann K., a,
READ
EMAIL
Bayer logo

You are encouraged to report side effects or quality complaints of products to the FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088. For Bayer products, you can report these directly to Bayer by clicking here.

 

This site provides access to balanced and evidence-based medical information related to our therapeutic areas of focus and is intended to serve as a medical resource for US HCPs. This may include investigational compounds or investigational new uses of FDA-approved Bayer products. The information provided is not intended to be promotional or provide medical advice. Please refer to the full Prescribing Information for approved indications, contraindications, warnings and precautions, and adverse events.

 

© 2026 Bayer. Bayer and the Bayer Cross are registered trademarks of Bayer.

Site last updated 02/2026